WAT

Business profile & competitive position

Waters Corporation operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. Its core business is designing, manufacturing, selling and servicing analytical instruments—chiefly high-performance and ultra-performance liquid chromatography (LC), mass spectrometry (MS), thermal analysis, rheometry and calorimetry (TA) systems—alongside the consumables, software and service contracts that keep them running. Following the February 2026 close of the BD Biosciences and Diagnostic Solutions acquisition, Waters also offers diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry and multiomics tools. In 2025, 59% of net sales went to pharmaceutical accounts, 30% to other industrial accounts and 11% to academic and government agencies, and no single customer represented more than 2% of net sales.

The installed base creates a natural recurring-revenue stream. Service revenue represented more than 35% of Waters’ 2025 sales and more than 25% of TA’s 2025 sales. That service attach rate usually indicates high customer switching costs and a moat built on instrument compatibility, validated methods and long-term support contracts. Yet the current margin figures temper that picture: a 3.6% net margin and 1.9% ROE are unusually low for a premium analytical-instrument franchise. Those numbers imply that reported profitability today is being absorbed by acquisition integration, elevated R&D or purchase-accounting effects rather than by a weak core competitive position.

Financial posture

Waters currently carries a $30.5 billion market capitalization and trades at a 101.4 P/E ratio as of the latest snapshot. Those multiples sit well above what the present earnings power would normally support, with a 3.6% net margin and 1.9% ROE. The gap between valuation and current profitability is the market’s real expectation that the BD Biosciences and Diagnostic Solutions combination will reshape revenue scale and margin structure over time. The transaction closed on February 9, 2026 for a total purchase price of $16.8 billion, including assumed debt, and BD shareholders own roughly 39.2% of the combined company.

Risk-wise, the beta of 1.18 means the stock has tended to move about 18% more than the broad market. At $407.74, the price is above the 50-day EMA of $379.48, and the RSI of 62.8 sits in neutral-to-warm territory rather than flashing an extreme overbought reading. The balance sheet is now anchored by one of the largest med-tech acquisitions of 2026, so debt service, goodwill accounting and integration execution deserve as much attention as organic order growth.

Strategic priorities & outlook

Waters’ most recent 10-K outlines a company in transition. Management plans to reorganize the combined company into four reporting segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences. The filing notes that Waters will evaluate the newly organized business activities to determine operating and reporting segments for future periods, so segment disclosures are likely to evolve through the next several filings.

Beyond reorganization, the 10-K emphasizes continued significant R&D investment to develop new products and enhance existing LC, MS, TA and diagnostics offerings. It also points to pursuing additional outsourcing opportunities as they arise while maintaining adequate internal supply chain and manufacturing capabilities. In plain terms, Waters is trying to integrate a diagnostics business roughly its own size, keep instrument innovation moving, and decide which operations it owns versus which it contracts out.

Macro & geopolitical exposure

As a Healthcare / Medical – Diagnostics & Research name, Waters faces macro and policy currents that matter even if they do not show up in any single headline. Pharmaceutical customers account for the majority of revenue, so the health of global drug-discovery budgets, biotech funding and generic-formulation spending directly affects instrument demand. Academic and government buyers represent 11% of sales, making National Institutes of Health and broader public-research appropriations relevant.

Because Waters instruments are precision-manufactured in a global supply chain and sold worldwide, tariffs, export controls and currency translation are ongoing variables. Regulatory clearances for new diagnostic platforms, especially anything tied to infectious-disease or cancer testing, also shape launch timing. Finally, any changes to healthcare reimbursement or diagnostic testing regulation in the United States, European Union or China can alter the economics of the newly acquired diagnostics business.

Recent developments

The most recent headlines are institution-focused and post-earnings. On August 15, 2026, defenseworld.net reported that Assetmark Inc. holds a $1.57 million stake in Waters. Two days earlier, on August 10, 2026, Dudley & Shanley Inc. disclosed an $8.85 million position, while the same outlet noted that a Waters director sold $1,442,930.44 in stock. On August 9, 2026, marketbeat.com published Waters Q2 earnings call highlights following the August 4, 2026 report.

Those filings arrived after the company beat the second-quarter 2026 EPS estimate with actual earnings of $3.05 versus $3.01 expected, producing a 1.3% positive surprise. The stock rose 0.99% the next session and 4.78% over the following five trading days, suggesting that fresh institutional disclosures and management commentary continued to draw attention after the immediate earnings reaction.

Earnings behavior & post-earnings drift

Waters has an eight-quarter earnings streak of 8 beats in 8 reports, or a 100% beat rate. The average earnings surprise across those quarters is 4.7%, and the average 5-day price move after reporting is 2.67% to the upside. That post-earnings drift is classified as “up,” meaning the stock has tended to extend its initial move rather than revert it.

The last four reports show the pattern has not been uniform. On August 4, 2026 the company reported $3.05 EPS versus a $3.01 estimate, a 1.3% beat that produced a 0.99% next-day gain and a 4.78% five-day gain. On May 5, 2026 the $2.70 actual versus $2.31 estimate represented a 16.9% surprise and brought a 2.04% next-day move and a 2.83% five-day move. February 9, 2026 was the outlier: $4.53 versus $4.51, only a 0.4% beat, with the stock slipping 0.34% the next day and 2.04% over the next five sessions. Going back to November 4, 2025, a $3.40 actual versus $3.21 estimate, a 5.9% beat, produced a 1.26% next-day gain and a 5.12% five-day gain. The next scheduled report is November 3, 2026 before the open, with the consensus EPS estimate at $4.01.

For investors who want to move beyond the headline numbers, the full institutional verdict on WAT—including sell-side ratings, price-target dispersion, short-interest trends and options positioning around the November 3, 2026 earnings date—is the next logical step. That broader view helps separate the mechanical post-earnings drift from the strategic thesis that the current 101.4 P/E and 1.9% ROE are implicitly pricing in.